Maria Sundvall
MD PhD; Specialist Physician in Clinical Oncology
mahesu@utu.fi Kiinamyllynkatu 10 Turku |
Areas of expertise
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
Biography
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Research
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Teaching
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Publications 
3 of 5
- Role of Ubiquitin and SUMO in Intracellular Trafficking (2019) SUMOylation and Ubiquitination: Current and Emerging Concepts Maria Sundvall
(Other publication) - Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin (2018)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase (2017)
- Journal of Biological Chemistry
(A1 Refereed original research article in a scientific journal) - ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer (2014)
- PLoS ONE
(A1 Refereed original research article in a scientific journal) - A metabolic prosurvival role for PML in breast cancer (2012)
- Journal of Clinical Investigation
(A1 Refereed original research article in a scientific journal) - Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein (2012)
- Journal of Biological Chemistry
(A1 Refereed original research article in a scientific journal) - Function of ERBB4 is determined by alternative splicing. (2011)
- Cell Cycle
(A1 Refereed original research article in a scientific journal) - Cell Death or Survival Promoted by Alternative Isoforms of ErbB4 (2010)
- Molecular Biology of the Cell
(A1 Refereed original research article in a scientific journal) - EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma (2010)
- Expert Opinion on Emerging Drugs
(A2 Refereed review article in a scientific journal ) - Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro (2009)
- Radiotherapy and Oncology
(A1 Refereed original research article in a scientific journal)
UTU Research Portal